Global agreement on CRISPR patent portfolio

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics said the companies and their licensors entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

The parties to the agreement include the co-owners of the intellectual property — the Regents of the University of California, Emmanuelle Charpentier and the University of Vienna — as well as key licensees and sublicensees CRISPR Therapeutics, ERS Genomics, Caribou Biosciences and Intellia Therapeutics.

Under the agreement, the parties commit to maintain and coordinate the prosecution, defense and enforcement of the CRISPR/Cas9 foundational patent portfolio worldwide, and each of the co-owners of the intellectual property grants cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.

“We are pleased that we have come to this global agreement with Intellia, Caribou, ERS and the co-owners and other licensees of this foundational CRISPR/Cas9 technology IP,” said Rodger Novak, CEO of CRISPR Therapeutics.

“We believe that the Charpentier-University of California-Vienna IP estate constitutes the foundational IP in the CRISPR/Cas9 editing space.

“Intellia, CRISPR Therapeutics,  Caribou, and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing development of our product candidates, as well as those of our corresponding partners and licensees.”

Intellia Therapeutics CEO Nessan Bermingham said: “Through this agreement, we are ensuring alignment in our efforts to protect and prosecute the foundational CRISPR/Cas9 discoveries made by Dr. Doudna, Dr. Charpentier, and their teams, which have transformed the genomics field and unleashed new therapeutic possibilities.

“This strengthens Intellia’s IP position as we continue forging ahead with the discovery and development of therapies for patients worldwide.”

Caribou Biosciences CEO Rachel Haurwitz said: “We appreciate the efforts of the co-owners and licensees to finalize this agreement and are pleased to move forward as each of our companies develops products using this breakthrough CRISPR/Cas9 foundational IP.”